In focus · trending topic

SB204

9 stories · following the connections

Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne

By Nasdaq OMXFeb 13, 2018, 1:05 PM UTC

Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution

By Nasdaq OMXNov 7, 2017, 1:05 PM UTC

Novan Conducts Guidance Meeting with FDA on SB204 Development Program

By Nasdaq OMXSep 25, 2017, 12:01 PM UTC

Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology

By Nasdaq OMXJul 7, 2017, 1:05 PM UTC

Novan Presents Safety Data for SB204 Program

By Nasdaq OMXApr 27, 2017, 1:14 PM UTC

Novan Provides Update on SB204 Development Program

By Nasdaq OMXMar 6, 2017, 11:05 AM UTC

Novan Announces SB204 Program Update Conference Call and Webcast

By Nasdaq OMXMar 3, 2017, 9:05 PM UTC

Novan Licenses SB204 to Sato for Acne in Japan

By Nasdaq OMXJan 17, 2017, 2:05 PM UTC